Cover Image

Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xiaoxiao Fan, Chenxi Wei, Minjun Rong, Shengnan Wang, Jiaying Wang, Xiaohan Wang, Xiao Han, Xue Meng
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	International Journal of Cancer
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
by: Pengcheng Zhu, et al.
Published: (2024)

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
by: Shuling Shi, et al.
Published: (2024)

Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective
by: Yongyin Gao, et al.
Published: (2024)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024)

Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Jie Zhao, et al.
Published: (2024)

The effect of common medications on the efficacy of immune checkpoint inhibitors
by: Daria Brinzevich, et al.
Published: (2025)

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer
by: Zhuo Cheng, et al.
Published: (2024)

Correction to “The effect of common medications on the efficacy of immune checkpoint inhibitors”
Published: (2026)

Revisiting the impact of common medications on immune checkpoint inhibitor efficacy
by: Parham Habibzadeh, et al.
Published: (2026)

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
by: Georges Gebrael, et al.
Published: (2024)

Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study
by: Mina Fazel, et al.
Published: (2025)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Gen Lin, et al.
Published: (2024)

Effect of body mass index and cholesterol‐rich apolipoprotein‐B‐containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors‐based therapy: A retrospective analysis
by: Zixin Hu, et al.
Published: (2024)

Lymphocyte activation markers predict the therapeutic response to immune checkpoint inhibitors: A case–control study
by: Takuya Iwamoto, et al.
Published: (2024)

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy
by: Jie Bian, et al.
Published: (2024)

Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment
by: Jiayi Wu, et al.
Published: (2024)

Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug‐resistant gestational trophoblastic neoplasia: Four case reports and literature review
by: Weiqing Liu, et al.
Published: (2024)

Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
by: Yi Zheng, et al.
Published: (2024)

Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
by: Hao Xiong, et al.
Published: (2024)

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
by: Yiran Rong, et al.
Published: (2024)

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
by: Xuemei Zhang, et al.
Published: (2024)

Interpretable machine learning model predicting immune checkpoint inhibitor‐induced hypothyroidism: A retrospective cohort study
by: Su‐Yan Zhu, et al.
Published: (2024)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024)

A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report
by: Yumiko Koi, et al.
Published: (2024)

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
by: Brie‐Anne Mannah, et al.
Published: (2025)

Immune checkpoint inhibitors increase the risk of psoriasis
by: Mary Beth Nierengarten
Published: (2025)

Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
by: Soh Mee Park, et al.
Published: (2024)

Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
by: Guiming Deng, et al.
Published: (2024)

A prediction model for response to immune checkpoint inhibition in advanced melanoma
by: Isabella A. J. van Duin, et al.
Published: (2024)

Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis
by: Toru Kadono, et al.
Published: (2024)

Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
by: Angela E. Alnemri, et al.
Published: (2024)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
by: Tadashi Nishimura, et al.
Published: (2024)

Mechanisms of enhancer‐driven oncogene activation
by: Joyce Vriend, et al.
Published: (2025)

Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis
by: Wenhua Song, et al.
Published: (2024)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024)

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers
by: Ying L. Liu, et al.
Published: (2024)

A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors
by: Takamasa Fujita, et al.
Published: (2026)

Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study
by: Takahiro Inoue, et al.
Published: (2026)

The implications of the TNFα‐TNFR2 immune checkpoint signaling pathway in cancer treatment: From immunoregulation to angiogenesis
by: Melissa Emamalipour, et al.
Published: (2024)

The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors
by: I. M. Horstman, et al.
Published: (2024)